ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS ESCI Q3Scopus Q2SCImago #9,237Gold OA

Chinese Clinical Oncology

Identifier (ISSN):2304-3865(Print)/2304-3873(Online)
•
Publisher:AME Publishing Company
Clarivate JCR Index Advisory: Active (ESCI)
Clarivate IF (2026)
2.7↑ +0.2
Journal Impact Factor
IF Trend↓
WoS Quartile
Q3
WoS ESCIJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2023–2026)

Clarivate IF trend for Chinese Clinical Oncology

WoS Q3
12342.820232.120242.520252.72026
Annual Impact Factor Metric
Current (2026):2.7
Scopus SJR & RankScopus Q2
0.636
#9,237

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
44

44 papers with at least that number of citations each

WoS: ESCIQ3
Self-Citation Rate4.8%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessGold OA
48articles/year
100% Gold OA•13.79% Original Research

Aims & Scope

The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.

Topics Covered (Recognized by AI)
Medicine99.6%Biology96.6%Internal medicine96.4%Genetics91.3%Pathology73.3%Cancer69.3%Surgery62.4%Oncology54.6%Chemistry50.7%Biochemistry39.4%Immunology35.8%Chemotherapy33.9%Cancer research32.8%Radiology30.8%Gastroenterology27.3%Mathematics21.7%Gene20.6%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRESCI2026

ONCOLOGY

Q3
Rank185/333
IndexESCI
JCIESCI2026

ONCOLOGY

Q4
Rank275/333
IndexESCI

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF2.7
Articles / Year64
Total Citations15
2025
IF2.5
Articles / Year78
Total Citations76
2024
IF2.1
Articles / Year180
Total Citations342
2023
IF2.8
Articles / Year77
Total Citations513
2022
IF—
Articles / Year48
Total Citations384

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #9,237Scopus Q2SCImago Profile
Scopus Coverage:2012-2026
Scopus Broad Areas:Medicine
Scopus Citation Rank (SJR)Q2
0.636

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
1.94

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,060 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations416
3-Year Documents212
Citable Documents153

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate33.8%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Medicine (miscellaneous)Q2
OncologyQ3
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 4.8%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
4区 (Zone 4)Medicine
Minor Category (Specific Field):
4区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Chinese Clinical Oncology (ISSN: 2304-3865) is a peer-reviewed international scholarly journal in the field of ONCOLOGY, published by AME Publishing Company in Hong Kong. The periodical holds a Journal Impact Factor (JIF) of 2.70, ranking in quartile Q3 of Web of Science (ESCI), a Scopus SJR indicator of 0.636 (Q2), an H-index of 44.

The journal enforces rigorous peer evaluation with an annual output of approximately 48 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,060 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Gold OA
Publisher
AME Publishing Company
Publication Language
English
Frequency
Periodic
Indexing & Databases
ESCIScopusPubMed

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 9e24f94c-6ccf-4bf9-a576-d73fc58cca16
Database Updated: 2026-09-29